PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

New facility to support advancements in molecular diagnostics, rare disease research, and industrial microbiology ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR screening libraries are collections of carefully designed single-guide RNAs (sgRNAs) that allow researchers to ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...